Structure-Guided design of antibodies

Current Computer-Aided Drug Design

Volumn 6, Issue 2, 2010, Pages 128-138

  Caravella, Justin A ^a   Wang, Deping ^a   Glaser, Scott M ^a   Lugovskoy, Alexey ^a  

^a BIOGEN   (United States)

Author keywords

Affinity maturation; Antibody engineering; Effector function; Protein stability; Structure based design

Indexed keywords

DESIGN; ENGINEERING EDUCATION; MONOCLONAL ANTIBODIES;

AFFINITY MATURATION; ANTIBODY ENGINEERING; BIOLOGICAL AGENTS; BIOPHYSICAL METHODS; EFFECTOR FUNCTION; HIGH AFFINITY; HIGH SPECIFICITY; HYBRIDOMA TECHNOLOGY; PROTEIN STABILITY; STRUCTURE-BASED DESIGNS;

ANTIGENS;

ANTIBODY; BEVACIZUMAB; CETUXIMAB; FC RECEPTOR; MONOCLONAL ANTIBODY;

ANTIBODY ENGINEERING; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG DESIGN; DRUG SPECIFICITY; HUMAN; NONHUMAN; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER AIDED DESIGN; DRUG STABILITY; IMMUNOLOGY; PROCEDURES; PROTEIN ENGINEERING;

ANTIBODIES, MONOCLONAL; COMPUTER-AIDED DESIGN; DRUG DESIGN; DRUG STABILITY; MOLECULAR STRUCTURE; PROTEIN ENGINEERING;

EID: 77953660480     PISSN: 15734099     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340910791202469     Document Type: Article

References (100)

1. Lefranc, M.P. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res., 2001, 29, 207-209.
2. Lefranc, M.; Giudicelli, V.; Ginestoux, C.; Jabado-Michaloud, J.; Folch, G.; Bellahcene, F.; Wu, Y.; Gemrot, E.; Brochet, X.; Lane, J.; Regnier, L.; Ehrenmann, F.; Lefranc, G.; Duroux, P. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res., 2009, 37, D1006-1012.
3. Reichert, J.M. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol., 2008, 9, 423-430.
4. Swann, P.G.; Tolnay, M.; Muthukkumar, S.; Shapiro, M.A.; Rellahan, B.L.; Clouse, K.A. Considerations for the development of therapeutic monoclonal antibodies. Curr. Opin. Immunol., 2008, 20, 493-499.
5. Presta, L.G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol, 2008, 20, 460-470.
6. Cohen-Solal, J.F.G.; Cassard, L.; Fridman, W.; Sautès-Fridman, C. Fc gamma receptors. Immunol. Lett., 2004, 92, 199-205.
7. Di Gaetano, N.; Cittera, E.; Nota, R.; Vecchi, A.; Grieco, V.; Scanziani, E.; Botto, M.; Introna, M.; Golay, J. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol., 2003, 171, 1581.
8. Brambell, F.W.; Hemmings, W.A.; Morris, I.G. A theoretical model of gamma-globulin catabolism. Nature, 1964, 203, 1352-1354.
9. Heyman, B. Complement and Fc-receptors in regulation of the antibody response. Immunol. Lett., 1996, 54, 195-199.
10. Wedemayer, G.J.; Patten, P.A.; Wang, L.H.; Schultz, P.G.; Stevens, R.C. Structural insights into the evolution of an antibody combining site. Science, 1997, 276, 1665-1669.
11. Chong, L.T.; Duan, Y.; Wang, L.; Massova, I.; Kollman, P.A. Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7. Proc. Natl. Acad. Sci. USA, 1999, 96, 14330-14335.
12. Midelfort, K.S.; Hernandez, H.H.; Lippow, S.M.; Tidor, B.; Drennan, C.L.; Wittrup, K.D. Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody. J. Mol. Biol., 2004, 343, 685-701.
13. MacCallum, R.M.; Martin, A.C.; Thornton, J.M. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol., 1996, 262, 732-745.
14. Sundberg, E.J.; Mariuzza, R.A. Molecular recognition in antibody-antigen complexes. Adv. Protein Chem., 2002, 61, 119-160.
15. Li, Y.; Li, H.; Yang, F.; Smith-Gill, S.J.; Mariuzza, R.A. X-ray snapshots of the maturation of an antibody response to a protein antigen. Nat. Struct. Biol., 2003, 10, 482-488.
16. Hofstädter, K.; Stuart, F.; Jiang, L.; Vrijbloed, J. W.; Robinson, J. A. On the importance of being aromatic at an antibody-protein antigen interface: mutagenesis of the extracellular interferon gamma receptor and recognition by the neutralizing antibody A6. J. Mol. Biol., 1999, 255, 805-815.
17. Acchione, M.; Lipschultz, C.A.; DeSantis, M. E.; Shanmuganathan, A.; Li, M.; Wlodawer, A.; Tarasov, S.; Smith-Gill, S.J. Light chain somatic mutations change thermodynamics of binding and water coordination in the HyHEL-10 family of antibodies. Mol. Immunol., 2009, 47, 457-464.
18. Tsumoto, K.; Ueda, Y.; Maenaka, K.; Watanabe, K.; Ogasahara, K.; Yutani, K.; Kumagai, I. Contribution to antibody-antigen interaction of structurally perturbed antigenic residues upon antibody binding. J. Biol. Chem., 1994, 269, 28777-28782.
19. Thorpe, I.F.; Brooks, C.L. Molecular evolution of affinity and flexibility in the immune system. Proc. Natl. Acad. Sci. USA, 2007, 104, 8821-8826.
20. Lo Conte, L.; Chothia, C.; Janin, J. The atomic structure of protein-protein recognition sites. J. Mol. Biol., 1999, 285, 2177-2198.
21. Clark, L.A.; Ganesan, S.; Papp, S.; van Vlijmen, H.W.T. Trends in antibody sequence changes during the somatic hypermutation process. J. Immunol., 2006, 177, 333-340.
22. Rubinstein, N.D.; Mayrose, I.; Halperin, D.; Yekutieli, D.; Gershoni, J.M.; Pupko, T. Computational characterization of B-cell epitopes. Mol. Immunol., 2008, 45, 3477-3489.
23. Das, R.; Baker, D. Macromolecular modeling with rosetta. Annu. Rev. Biochem., 2008, 77, 363-382.
24. Clark, L.A.; Boriack-Sjodin, P.A.; Eldredge, J.; Fitch, C.; Friedman, B.; Hanf, K.J.M.; Jarpe, M.; Liparoto, S.F.; Li, Y.; Lugovskoy, A.; Miller, S.; Rushe, M.; Sherman, W.; Simon, K.; Van Vlijmen, H. Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci., 2006, 15, 949-960.
25. Benson, D.E.; Wisz, M.S.; Liu, W.; Hellinga, H.W. Construction of a novel redox protein by rational design: conversion of a disulfide bridge into a mononuclear iron-sulfur center. Biochemistry, 1998, 37, 7070-7076.
26. Spector, S.; Sauer, R.T.; Tidor, B. Computational and experimental probes of symmetry mismatches in the Arc repressor-DNA complex. J. Mol. Biol., 2004, 340, 253-261.
27. Kirk, A.D.; Burkly, L.C.; Batty, D.S.; Baumgartner, R.E.; Berning, J.D.; Buchanan, K.; Fechner, J.H.; Germond, R.L.; Kampen, R.L.; Patterson, N.B.; Swanson, S.J.; Tadaki, D.K.; TenHoor, C.N.; White, L.; Knechtle, S.J.; Harlan, D.M. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med., 1999, 5, 686-693.
28. Van Vlijmen, H.; Sherman, B.W.H.; Lugovskoy, A.A. Altered antibodies having improved antigen-binding affinity. W0/2005/011376.
29. Lippow, S.M.; Wittrup, K.D.; Tidor, B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat. Biotechnol., 2007, 25, 1171-1176.
30. Sivasubramanian, A.; Sircar, A.; Chaudhury, S.; Gray, J.J. Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking. Proteins, 2009, 74, 497-514.
31. Barderas, R.; Desmet, J.; Timmerman, P.; Meloen, R.; Casal, J.I. Affinity maturation of antibodies assisted by in silico modeling. Proc. Natl. Acad. Sci. USA, 2008, 105, 9029-9034.
32. Mohan, S.; Kourentzi, K.; Schick, K.A.; Uehara, C.; Lipschultz, C.A.; Acchione, M.; Desantis, M. E.; Smith-Gill, S.J.; Willson, R.C. Association energetics of cross-reactive and specific antibodies. Biochemistry, 2009, 48, 1390-1398.
33. Farady, C.J.; Sellers, B.D.; Jacobson, M.P.; Craik, C.S. Improving the species cross-reactivity of an antibody using computational design. Bioorg. Med. Chem. Lett., 2009, 19, 3744-3747.
34. Almagro, J.C.; Fransson, J. Humanization of antibodies. Front. Biosci., 2008, 13, 1619-1633.
35. Jones, P.T.; Dear, P.H.; Foote, J.; Neuberger, M.S.; Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature, 1986, 321, 522-525.
36. Verhoeyen, M.; Milstein, C.; Winter, G. Reshaping human antibodies: grafting an antilysozyme activity. Science, 1988, 239, 1534-1536.
37. Queen, C.; Schneider, W.P.; Selick, H. E.; Payne, P. W.; Landolfi, N. F.; Duncan, J. F.; Avdalovic, N. M.; Levitt, M.; Junghans, R.P.; Waldmann, T.A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA, 1989, 86, 10029-10033.
38. Chothia, C.; Lesk, A.M. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol., 1987, 196, 901-917.
39. Al-Lazikani, B.; Lesk, A.M.; Chothia, C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol., 1997, 273, 927-948.
40. Carter, P.; Presta, L.; Gorman, C.M.; Ridgway, J.B.; Henner, D.; Wong, W.L.; Rowland, A.M.; Kotts, C.; Carver, M.E.; Shepard, H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 1992, 89, 4285-4289.
41. Rodrigues, M.L.; Shalaby, M.R.; Werther, W.; Presta, L.; Carter, P. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells. Int. J. Cancer Suppl., 1992, 7, 45-50.
42. Presta, L.G.; Chen, H.; O'Connor, S.J.; Chisholm, V.; Meng, Y. G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57, 4593-4599.
43. Tan, P.; Mitchell, D.A.; Buss, T.N.; Holmes, M.A.; Anasetti, C.; Foote, J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J. Immunol., 2002, 169, 1119-1125.
44. Hwang, W.Y.K.; Almagro, J.C.; Buss, T.N.; Tan, P.; Foote, J. Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods, 2005, 36, 35-42.
45. Lazar, G.A.; Desjarlais, J.R.; Jacinto, J.; Karki, S.; Hammond, P.W. A molecular immunology approach to antibody humanization and functional optimization. Mol. Immunol., 2007, 44, 1986-1998.
46. Bernett, M.J.; Karki, S.; Moore, G.L.; Leung, I.W.L.; Chen, H.; Pong, E.; Nguyen, D.T.; Jacinto, J.; Zalevsky, J.; Muchhal, U.S.; Desjarlais, J.R.; Lazar, G.A. Engineering fully human monoclonal antibodies from murine variable regions. J. Mol. Biol., 2010.
47. Padlan, E.A. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol., 1991, 25, 489-498.
48. Mimura, Y. Role of oligosaccharide residues of IgG1-Fc in Fcgamma RIIb binding. J. Biol. Chem., 2001, 276, 45539-45547.
49. Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med., 2000, 6, 443-446.
50. Desjarlais, J.R.; Lazar, G.A.; Zhukovsky, E.A.; Chu, S.Y. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov. Today, 2007, 12, 898-910.
51. Shields, R.L. High resolution mapping of the binding site on human IgG1 for Fcgamma RI, Fcgamma RII, Fcgamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fcgamma R. J. Biol. Chem., 2000, 276, 6591-6604.
52. Uma a, P.; Jean-Mairet, J.; Moudry, R.; Amstutz, H.; Bailey, J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotech., 1999, 17, 176-180.
53. Sondermann, P.; Huber, R.; Oosthuizen, V.; Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature, 2000, 406, 267-273.
54. Lazar, G.A.; Dang, W.; Karki, S.; Vafa, O.; Peng, J. S.; Hyun, L.; Chan, C.; Chung, H.S.; Eivazi, A.; Yoder, S.C.; Vielmetter, J.; Carmichael, D.F.; Hayes, R.J.; Dahiyat, B.I. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA, 2006, 103, 4005-4010.
55. Richards, J.O.; Karki, S.; Lazar, G.A.; Chen, H.; Dang, W.; Desjarlais, J.R. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther., 2008, 7, 2517-2527.
56. Oganesyan, V.; Damschroder, M.M.; Leach, W.; Wu, H.; Dall'Acqua, W.F. Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol. Immunol., 2008, 45, 1872-1882.
57. Feige, M.J.; Nath, S.; Catharino, S.R.; Weinfurtner, D.; Steinbacher, S.; Buchner, J. Structure of the murine unglycosylatedIgG1 Fc fragment. J. Mol. Biol., 2009, 391, 599-608.
58. Oganesyan, V.; Gao, C.; Shirinian, L.; Wu, H.; Dall'Acqua, W.F. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. D Biol. Crystallogr., 2008, 64, 700-704.
59. Ghetie, V.; Ward, E.S. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu. Rev. Immunol., 2000, 15, 739-766.
60. Olafsen, T.; Kenanova, V.E.; Wu, A.M. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat. Protoc., 2006, 1, 2048-2060.
61. Raghavan, M.; Bonagura, V.R.; Morrison, S.L.; Bjorkman, P.J. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry, 1995, 34, 14649-14657.
62. Medesan, C.; Matesoi, D.; Radu, C.; Ghetie, V.; Ward, E.S. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J. Immunol., 1997, 155, 2211.
63. Burmeister, W.P.; Huber, A.H.; Bjorkman, P.J. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature, 1994, 372, 379-383.
64. Presta, L.G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol., 2008, 20, 460-470.
65. Yeung, Y.A.; Leabman, M.K.; Marvin, J.S.; Qiu, J.; Adams, C.W.; Lien, S.; Starovasnik, M.A.; Lowman, H.B. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J. Immunol., 2009, 152, 7663.
66. Dall'Acqua, W.F.; Woods, R.M.; Ward, E.S.; Palaszynski, S.R.; Patel, N.K.; Brewah, Y.A.; Wu, H.; Kiener, P.A.; Langermann, S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol., 2002, 169, 5171-5180.
67. Dall'Acqua, W.F. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc Receptor (FcRn). J. Biol. Chem., 2006, 251, 23514-23524.
68. Idusogie, E.E.; Presta, L.G.; Gazzano-Santoro, H.; Totpal, K.; Wong, P.Y.; Ultsch, M.; Meng, Y.G.; Mulkerrin, M.G. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol., 2000, 164, 4178.
69. Zalevsky, J.; Chamberlain, A.K.; Horton, H.M.; Karki, S.; Leung, I.W.L.; Sproule, T.J.; Lazar, G.A.; Roopenian, D.C.; Desjarlais, J. R. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol, 2010.
70. Demarest, S.J.; Glaser, S.M. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr. Opin. Drug Discov. Dev., 2008, 11, 675-687.
71. Glockshuber, R.; Malia, M.; Pfitzinger, I.; Pluckthun, A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry, 1990, 29, 1362-1367.
72. Jung, S.H.; Pastan, I.; Lee, B. Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins, 1994, 19, 35-47.
73. Rodrigues, M.L.; Presta, L. G.; Kotts, C.E.; Wirth, C.; Mordenti, J.; Osaka, G.; Wong, W.L.; Nuijens, A.; Blackburn, B.; Carter, P. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res., 1995, 55, 63-70.
74. Young, N.M.; MacKenzie, C.R.; Narang, S.A.; Oomen, R.P.; Baenziger, J.E. Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond. FEBS Lett., 1995, 577, 135-139.
75. Langedijk, A.C.; Honegger, A.; Maat, J.; Planta, R.J.; van Schaik, R.C.; Pluckthun, A. The nature of antibody heavy chain residue H6 strongly influences the stability of a VH domain lacking the disulfide bridge. J. Mol. Biol., 1998, 283, 95-110.
76. Kipriyanov, S.M.; Moldenhauer, G.; Martin, A.C.; Kupriyanova, O.A.; Little, M. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng., 1997, 10, 445-453.
77. Honegger, A.; Pluckthun, A. The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains. J. Mol. Biol., 2001, 309, 687-699.
78. Jung, S.; Spinelli, S.; Schimmele, B.; Honegger, A.; Pugliese, L.; Cambillau, C.; Pluckthun, A. The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains. J. Mol. Biol., 2001, 309, 701-716.
79. Ewert, S.; Huber, T.; Honegger, A.; Pluckthun, A. Biophysical properties of human antibody variable domains. J. Mol. Biol., 2003, 325, 531-553.
80. Knappik, A.; Ge, L.; Honegger, A.; Pack, P.; Fischer, M.; Wellnhofer, G.; Hoess, A.; Wolle, J.; Pluckthun, A.; Virnekas, B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol., 2000, 296, 57-86.
81. Ewert, S.; Honegger, A.; Pluckthun, A. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach. Biochemistry, 2003, 42, 1517-1528.
82. Ewert, S.; Honegger, A.; Pluckthun, A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods, 2004, 34, 184-199.
83. Honegger, A.; Malebranche, A.D.; Rothlisberger, D.; Pluckthun, A. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains. Protein Eng. Des. Sel., 2009, 22, 121-134.
84. Garber, E.; Demarest, S.J. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem. Biophys. Res. Commun., 2007, 355, 751-757.
85. Nieba, L.; Honegger, A.; Krebber, C.; Pluckthun, A. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng., 1997, 10, 435-444.
86. Chowdhury, P.S.; Vasmatzis, G.; Beers, R.; Lee, B.; Pastan, I. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. J. Mol. Biol., 1998, 281, 917-928.
87. Wang, N.; Smith, W.F.; Miller, B.R.; Aivazian, D.; Lugovskoy, A.A.; Reff, M.E.; Glaser, S.M.; Croner, L.J.; Demarest, S.J. Conserved amino acid networks involved in antibody variable domain interactions. Proteins, 2009, 76, 99-114.
88. Wörn, A.; Plückthun, A. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry, 1998, 37, 13120-13127.
89. Wörn, A.; Plückthun, A. Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry, 1999, 38, 8739-8750.
90. Röthlisberger, D.; Honegger, A.; Plückthun, A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J. Mol. Biol., 2005, 347, 773-789.
91. Barthelemy, P.A.; Raab, H.; Appleton, B.A.; Bond, C.J.; Wu, P.; Wiesmann, C.; Sidhu, S.S. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem., 2008, 283, 3639-3654.
92. Ewert, S.; Cambillau, C.; Conrath, K.; Pluckthun, A. Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry, 2002, 41, 3628-3636.
93. McAuley, A.; Jacob, J.; Kolvenbach, C. G.; Westland, K.; Lee, H. J.; Brych, S.R.; Rehder, D.; Kleemann, G.R.; Brems, D.N.; Matsumura, M. Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain. Protein Sci., 2008, 17, 95-106.
94. Gong, R.; Vu, B.K.; Feng, Y.; Prieto, D.A.; Dyba, M.A.; Walsh, J.D.; Prabakaran, P.; Veenstra, T.D.; Tarasov, S.G.; Ishima, R.; Dimitrov, D.S. Engineered human antibody constant domains with increased stability. J. Biol. Chem., 2009, 284, 14203-14210.
95. Chennamsetty, N.; Helk, B.; Voynov, V.; Kayser, V.; Trout, B.L. Aggregation-prone motifs in human immunoglobulin G. J. Mol. Biol., 2009, 391, 404-413.
96. Chennamsetty, N.; Voynov, V.; Kayser, V.; Helk, B.; Trout, B.L. Design of therapeutic proteins with enhanced stability. Proc. Natl. Acad. Sci. USA, 2009, 106, 11937-11942.
97. Jordan, J.L.; Arndt, J.W.; Hanf, K.; Li, G.; Hall, J.; Demarest, S.; Huang, F.; Wu, X.; Miller, B.; Glaser, S.; Fernandez, E.J.; Wang, D.; Lugovskoy, A. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins, 2009, 77, 832-841.
98. Shen, J.; Vil, M.D.; Jimenez, X.; Iacolina, M.; Zhang, H.; Zhu, Z. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies. J. Biol. Chem., 2006, 281, 10706-10714.
99. Wu, C.; Ying, H.; Grinnell, C.; Bryant, S.; Miller, R.; Clabbers, A.; Bose, S.; McCarthy, D.; Zhu, R.; Santora, L.; Davis-Taber, R.; Kunes, Y.; Fung, E.; Schwartz, A.; Sakorafas, P.; Gu, J.; Tarcsa, E.; Murtaza, A.; Ghayur, T. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol., 2007, 25, 1290-1297.
100. Michaelson, J.S.; Demarest, S.J.; Miller, B.; Amatucci, A.; William, S.; Wu, X.; Huang, F.; Phan, S.; Gao, S.; Doern, A.; Farrington, G.K.; Lugovskoy, A.; Joseph, I.; Bailly, V.; Wang, X.; Garber, E.; Browning, J.; Glaser, S.M. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR. mAbs, 2009, 1, 128-141.